{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:892",
      "entity_text" : "MI",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5311272",
      "entity_text" : "DAPT",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In the DAPT trial, XREF_BIBR the largest and only double blinded study, extended DAPT (30 vs. 12 months) reduced the risk of major adverse cardiovascular and cerebrovascular events (4.3 vs. 5.9%), myocardial infarction (MI; 2.1 vs. 4.1%), and stent thrombosis (0.4 vs. 1.4%) but at a cost of increased moderate or severe bleeding (2.5 vs. 1.6%) and a borderline rise in all-cause mortality (2.0 vs. 1.0%; p = 0.05).",
  "reading_complete" : "2020-08-03T14:31:21Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T14:30:08Z",
  "trigger" : "reduced",
  "evidence" : [ "DAPT (30 vs. 12 months) reduced the risk of major adverse cardiovascular and cerebrovascular events (4.3 vs. 5.9%), myocardial infarction (MI" ],
  "pmc_id" : "6524921",
  "score" : 0
}